Investor's Business Daily on MSN5h
Bristol Myers Wallops Fourth-Quarter Views, But Shares Slide On 2025 Outlook
Bristol Myers walloped sales views Thursday, but Bristol Myers Squibb stock took a hit on a light outlook hamstrung by ...
Trade Tracker: Josh Brown sells Bristol Myers after buying it on Monday
Josh Brown, CEO of Ritholtz Wealth Management, joins CNBC's "Halftime Report" to explain why he's selling Bristol Myers so ...
Jim Cramer on Bristol-Myers Squibb (BMY): “First Schizophrenia Drug in 30 Years”
We recently published a list of Jim Cramer Tells Viewers To Not Trust Billionaires & Discusses These 11 Stocks. In this ...
Bristol-Myers Squibb targets $45.5B revenue for 2025 with cost savings and pipeline expansion
Financial discipline remained a priority, with approximately $1.1 billion of the targeted $1.5 billion in savings already realized. The company has identified an additional $2 billion in savings, with ...
Bristol Myers Wallops Fourth-Quarter Earnings Views. But Shares Plummet 5%.
Bristol Myers Squibb stock tumbled Thursday on a light outlook for 2025 following a strong fourth-quarter report.
Bristol Myers Earnings Are ‘a Tale of 2 Trends’ as Guidance Falls Short
The drugmaker Bristol Myers Squibb has been a standout among its big pharma peers over the past six months, scoring a ...